(S) TASIN 15
Alternative Names: (S)-TASIN-15Latest Information Update: 07 Dec 2023
At a glance
- Originator University of Texas Southwestern Medical Center
- Developer Barricade Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action EBP protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Colorectal cancer
Most Recent Events
- 24 Nov 2023 Barricade Therapeutics has patent protection for S TASIN 15 globally (Barricade Therapeutics pipeline, November 2023)
- 24 Nov 2023 Preclinical trials in Colorectal cancer in USA (PO) before November 2023 (Barricade Therapeutics pipeline, November 2023)
- 24 Nov 2023 Barricade Therapeutics announces intention to submit IND to for Colorectal cancer in 1H of 2024 (Barricade Therapeutics pipeline, November 2023)